Cobimetinib is a MEK inhibitor used in combination with other therapies to treat certain types of melanoma by blocking the MEK pathway, that is involved in cancer cell growth. It is grouped under the following drug class(es): Kinase inhibitors. Its therapeutic use is listed as anti-cancer agents and antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Cobimetinib Butyrate and Cotellic. Its PubChem CID is 16222096.
Cobimetinib
| CAS No | 934660-93-2 |
|---|---|
| Molecular Formula | C21H21F3IN3O2 |
| Molecular Weight | 531.3 g/mol |
| Synonyms | [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Cobimetinib is a MEK inhibitor used in combination with other therapies to treat certain types of melanoma by blocking the MEK pathway, that is involved in cancer cell growth.
The listed CAS number is 934660-93-2.
The listed molecular formula is C21H21F3IN3O2.
The listed molecular weight is 531.3 g/mol.
[3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone.
The source lists Cobimetinib Butyrate and Cotellic.